Clinical and Economic Impact of Herpes Zoster in Cancer Patients
Key facts
- Who runs it
- AC Camargo Cancer Center
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 150 people enrolled
- Started
- 1 Sept 2019
- Ended
- 30 Dec 2024
- Type of study
- Observational
- Treatments tested
- Herpes Zoster episode
- Record updated
- 19 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults (≥18 years)
- Active solid or hematologic malignancy
- Evaluation at A.C. Camargo Cancer Center (São Paulo, Brazil) between September 2019 and December 2024
- Clinically confirmed episode of herpes zoster (initial episode or recurrence)
- Herpes zoster diagnosed based on a typical painful dermatomal rash with polymorphic lesions (macules, papules, vesicles, and crusts), either localized or disseminated
Who cannot take part
- No evidence of active malignancy (complete remission or no oncologic treatment for at least one year)
- Age <18 years
- Patients in whom herpes zoster was not confirmed after medical record review
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Herpes zoster (HZ) is an important infectious complication among patients with cancer, particularly in the setting of treatment-related immunosuppression. This retrospective observational cohort study aimed to characterize the clinical profile of HZ episodes and estimate direct hospital costs associated with emergency department visits and hospitalizations in patients with active malignancy treated at a Brazilian tertiary cancer center. The study also explored associations between cancer characteristics, recent oncologic therapies, and clinical outcomes, including postherpetic neuralgia, recurrence, disease dissemination, and hospital costs. Findings are intended to support future budget impact and cost-effectiveness analyses of herpes zoster vaccination in oncology populations.
The group in the trial
- Patients with Herpes Zoster and Active Cancer
Adult patients with active solid or hematologic malignancies who presented with a clinically confirmed episode of herpes zoster between September 2019 and December 2024 at A.C. Camargo Cancer Center, São Paulo, Brazil.
Treatment: Herpes Zoster episode
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical and Economic Impact of Herpes Zoster in Cancer Patients - A Retrospective Cohort Study in a Brazilian Cancer Center
- Record updated
- 19 August 2026